PulmoGate raises approximately JPY330 million in Seed funding
Beyond Next Ventures leads financing for the Nagoya medical technology startup’s lung disease platform.
PulmoGate has raised approximately JPY330 million in a Seed round through a third-party share allotment. Beyond Next Ventures, Inc. led the round, joined by Teijin Pharma, Mitsubishi UFJ Capital Co., Ltd. and STATION Ai Central Japan 2-go Fund.
The Nagoya University research spinout focuses on interstitial lung disease. It is developing a remote multidisciplinary review service that brings specialist expertise into second opinions.
From specialist review to clinical development
The company plans to expand the remote review service, strengthen clinical validation and build its medical AI development and regulatory team. It is also researching AI for diagnosis and treatment strategy, alongside applications for home monitoring and respiratory rehabilitation. These products remain in development.
Use of funds
Remote specialist second-opinion service expansion
Clinical validation and medical AI development
Treatment support and home monitoring research